Truist initiated coverage of Hinge Health (HNGE) with a Buy rating and $48 price target Hinge is a market leader in digital musculoskeletal care with “enduring structural advantages,” the analyst tells investors in a research note. The firm says the company’s “robust” outcomes data, extensive partner network, AI-enabled platform, and “compelling economics create a flywheel of adoption, retention, and expansion.” Truist sees long-term value creation potential.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue